Bladder Cancer Advisor: The latest news, updated regimens, drug listings, and more.
View web version
Latest News
Ramucirumab Prolongs Progression-free Survival in Platinum-refractory Urothelial Cancer
Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma
Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers
Durvalumab May Be Effective as Second Line Therapy in Urothelial Carcinoma
Drug Listing
Bladder Cancer Drug Listing
Treatment Regimen
Bladder Cancer Treatment Regimen
Features
Can the FDA Curb Drug Prices for Cancer Treatment?
By
Industry Payments to Physicians: Confronting Conflicts of Interest
By
Monoclonal Antibodies as Immunotherapy "Magic Bullets"
By

Want to receive emails specific to your profession and specialty? Click here to complete your profile.



Subscribe
If you were sent this by a colleague and wish to subscribe to Daily Update, please click here.

Unsubscribe
To unsubscribe from Daily Update click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "email.cancertherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

© 2015 Haymarket Media Inc
275 7th Avenue, 10th Floorr
New York, NY 10001